Evaluation of serum adiponectin concentration in patients with type 2 diabetes
DOI:
https://doi.org/10.12923/Keywords:
adiponectin, adipose tissue, diabetesAbstract
Adiponectin, a recently discovered protein secreted exclusively and abundantly from adipose tissue, known as Acrp30 (adipocyte complement-related protein of 30kDa), AdipoQ, apM1 protein (adipose most abundant gene transcript-1), and GBP28 (gelatin-binding protein of 28kDa), comprises approximately 0.01% of the total plasma protein in healthy humans. Recent studies have suggested that circulating adiponectin is a bioactive protein with multivalent functions such as insulin sensitizing, anti-inflammatory, anti-atherogenic activities and also prevents endothelial dysfunction. Although its structure and source are known, the role and clinical implications of adiponectin have not been definitively established. The aim of this study was to evaluate serum adiponectin concentration in overweight and obese patients with type 2 diabetes, in comparison to healthy participants, and also assess the possible relationship of this cytokine with selected demographic, anthropometric and biochemical parameters. The study was conducted in 40 patients with diabetes type 2 with the average duration of the disease from diagnosis 9.4±8.1 years. Among the enrolled subjects were 17 women and 23 men with mean age 58.9±11.1 years. The control group was composed of 25 healthy subjects (11 women and 14 men) with the mean age of 55.3±7.1 years, with no disturbances in carbohydrate metabolism and with normal body mass. The mean adiponectin concentration in the study group was significantly lower compared to the control group. However, in the examined group the females had a significantly higher adiponectin level than males. We observed significant positive correlations between adiponectin concentration and age and level of HDL-cholesterol in the study group. Furthermore, significant negative correlations were found between adiponectin concentration and body mass, BMI, level of glucose, HbA1C, triglicerydes and activity of ALT, AST. In conclusion, we report that decreased adiponectin concentration in overweight and obese patients with type 2 diabetes in comparison to healthy subjects and the observed correlations of adiponectin with lipid metabolism parameters may suggest antiatherogenic effects of this protein.
References
1. Arita Y., Kihara S., Ouchi N. et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 257, 79, 1999.
2. Baratta R., Amato S., Degano C. et al.: Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J. Clin. Endocrinol. Metab., 89, 2665, 2004.
3. Boyne M.S., Bennett N.R., Cooper R.S. et al.: Sex-differences in adiponectin levels and body fat distribution: longitudinal observations in Afro-Jamaicans. Diabetes Res. Clin. Pract., 90(2), 33, 2010.
4. Cnop M., Havel P.J., Utzschneider K.M. et al.: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459, 2003.
5. Cnop M., Landchild M.J., Vidal J. et al.: The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes, 51, 1005, 2002.
6. Combs T.P., Berg A.H., Rajala M.W. et al.: Sexual differentiation, pregnancy, calorie restriction and aging affect the adipocytespecific secretory protein Acrp30/adiponectin. Diabetes, 52, 268, 2003.
7. Comuzzie A.G., Cianflone K., Martin L.J. et al.: Serum levels of acylation stimulating protein (ASP) show evidence of a pleiotropic relationship with total cholesterol, LDL, and triglycerides and preliminary evidence of linkage on chromosomes 5 and 17 in Mexican Americans. Obes. Res., 9, 103, 2001.
8. Ezenwaka C.E., Kalloo R., Uhlig M. et al.: Serum adiponectin levels and enzyme markers of liver dysfunction in diabetic and non-diabetic Caribbean subjects. Br. J. Biomed. Sci., 63(3), 117, 2006.
9. Esteghamati A., Alamdari A., Zandieh A. et al.: Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res. Clin. Pract., 91(2), 154, 2011.
10. Gavrila A., Chan J.L., Yiannakouris N. et al. Serum adiponectin levels are inversely associated with central fat distribution and estrogen levels but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J. Clin. Endocrinol. Metab., 88, 4823, 2003.
11. Havel P.J.: Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes, 53(1), 143, 2004.
12. Hotta K., Funahashi T., Arita Y. et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 20, 1595, 2000.
13. Hotta K., Funahashi T., Bodkin N.L. et al.: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 50, 1126, 2001.
14. Hu E., Liang P., Spiegelman B.M.: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem., 271, 10697, 1996.
15. Ioannis K., Sudhesh K.: Weight Management in Overweight and Obese Patients With Type 2 Diabetes Mellitus. The Br. J. Diabetes Vasc. Dis., 10(6), 274, 2010.
16. Kern P.A., Di Gregorio G.B., Lu T. et al.: Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes, 52,1779, 2003.
17. Lihn A.S., Bruun J.M., He G. et al.: Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol. Cell Endocrinol., 219, 9, 2004.
18. Matsubara M., Maruoka S., Katayose S.: Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab., 87(6), 2764, 2002.
19. Motoshima H., Wu X., Sinha M.K. et al.: Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab., 87, 5662, 2002.
20. Okamoto Y., Kihara S., Funahashi T. et al.: Adiponectin: a key adipocytokine in metabolic syndrome. Clin. Sci. (Lond), 110(3), 267, 2006.
21. Pagano C., Soardo G., Esposito W. et al.: Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur. J. Endocrinol., 152(1), 113, 2005.
22. Phillips L.K., Prins J.B.: The link between abdominal obesity and the metabolic syndrome. Current Hypertension Reports, 10(2), 156, 2008.
23. Ryo, M., Nakamura, T., Kihara, S. et al.: Adiponectin as a biomarker of the metabolic syndrome. Circ. J., 68, 975, 2004.
24. Shah S., Gavrila A., Mantzoros C.S. (2005). Adiponectin and the Cardiovascular System. In: Diabetes and Cardiovascular Disease. Johnstone Michael T., Veves Aristidis (editors). Boston: Humana Press; p.191.
25. Stefan N., Stumvoll M.: Adiponectin: its role in metabolism and beyond. Horm. Metab. Res. 34, 469, 2002.
26. Swarbrick M.M., Havel P.J.: Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab. Syndr. Relat. Disord., 6, 87, 2008.
27. Tilg H., Wolf A.M.: Adiponectin: a key fat-derived molecule regulating inflammation. Expert. Opin. Ther. Targets, 9(2), 245, 2005.
28. Trujillo M.E., Scherer P.E.: Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med., 257(2), 167, 2005.
29. Tschritter O., Fritsche A., Thamer C. et al.: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 52, 239, 2003.
30. Tsuda S., Nakano S., Konishi K. et al.: A lack of increase in high molecular weight-adiponectin in macroalbuminuric subjects with metabolic syndrome may exert renal and atherosclerotic risks. Diabetes Res. Clin. Pract., 79(3), 503, 2008.
31. Weyer C., Funahashi T., Tanaka S. et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab., 86, 193, 2001.
32. Yang W.S., Lee W.J., Funahashi T. et al.: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab., 86, 3815, 2001.
33. Yamamoto Y., Hirose H., Saito I. et al.: Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. (Lond), 103,137, 2002.
34. Zhuo Q., Wang Z., Fu P. et al.: Comparison of adiponectin, leptin and leptin to adiponectin ratio as diagnostic marker for metabolic syndrome in older adults of Chinese major cities. Diabetes Res. Clin. Pract., 84(1), 27, 2009.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
